AU2017363307B2 - Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof - Google Patents

Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof Download PDF

Info

Publication number
AU2017363307B2
AU2017363307B2 AU2017363307A AU2017363307A AU2017363307B2 AU 2017363307 B2 AU2017363307 B2 AU 2017363307B2 AU 2017363307 A AU2017363307 A AU 2017363307A AU 2017363307 A AU2017363307 A AU 2017363307A AU 2017363307 B2 AU2017363307 B2 AU 2017363307B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
certain embodiments
carbocyclyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017363307A
Other languages
English (en)
Other versions
AU2017363307A1 (en
Inventor
Nathanael S. Gray
Baishan JIANG
Nicholas Paul Kwiatkowski
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2017363307A1 publication Critical patent/AU2017363307A1/en
Application granted granted Critical
Publication of AU2017363307B2 publication Critical patent/AU2017363307B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017363307A 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof Active AU2017363307B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425519P 2016-11-22 2016-11-22
US62/425,519 2016-11-22
PCT/US2017/063132 WO2018098361A1 (en) 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof

Publications (2)

Publication Number Publication Date
AU2017363307A1 AU2017363307A1 (en) 2019-05-02
AU2017363307B2 true AU2017363307B2 (en) 2021-07-29

Family

ID=60703092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017363307A Active AU2017363307B2 (en) 2016-11-22 2017-11-22 Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof

Country Status (6)

Country Link
US (2) US11306070B2 (enExample)
EP (1) EP3544971B1 (enExample)
JP (1) JP7258748B2 (enExample)
AU (1) AU2017363307B2 (enExample)
CA (1) CA3041563C (enExample)
WO (1) WO2018098361A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
JP7258748B2 (ja) 2016-11-22 2023-04-17 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
SG11202013175SA (en) * 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
JP2022529700A (ja) * 2019-04-23 2022-06-23 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド サイクリン依存性キナーゼ１２（ｃｄｋ１２）の分解剤およびその使用
WO2020219926A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer with cdk inhibitors
CN114901284A (zh) * 2019-10-29 2022-08-12 希洛斯医药品股份有限公司 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
CN111269217B (zh) * 2020-04-07 2021-01-08 苏州信诺维医药科技有限公司 一种嘧啶胺类化合物、其制备方法及应用
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
US20230303512A1 (en) * 2020-08-26 2023-09-28 Massachusetts Institute Of Technology Modulators of myb-mediated transcription and uses thereof
IL310368A (en) 2021-08-18 2024-03-01 Chemocentryx Inc Arylsulfonyl(hydroxy)piperidines as CCR6 inhibitors
MX2024002173A (es) 2021-08-18 2024-03-26 Chemocentryx Inc Compuestos de arilsulfonilo como inhibidores de ccr6.
WO2023091726A1 (en) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin‑dependent kinase 12 (cdk12)
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用
WO2024186319A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations
WO2026165163A1 (en) * 2025-01-30 2026-08-06 Deciphera Pharmaceuticals, Llc Cdk inhibitors and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058126A1 (en) * 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en) * 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015154038A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) * 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
US6329380B1 (en) * 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
CA2584368A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
CA2593428C (en) 2005-01-10 2012-04-17 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
CA2744713A1 (en) 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
EP2397479A4 (en) 2009-02-12 2012-08-01 Astellas Pharma Inc HETERO RING DERIVATIVE
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
WO2015058163A2 (en) * 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7258748B2 (ja) 2016-11-22 2023-04-17 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
AU2017363390A1 (en) 2016-11-28 2019-06-13 Dana-Farber Cancer Institute, Inc. Reagents and methods for analysis of proteins and metabolites targeted by covalent probes
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN113164477A (zh) * 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
CA3166135A1 (en) * 2019-12-24 2021-07-01 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015058126A1 (en) * 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en) * 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015154038A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) * 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
EP3544971B1 (en) 2022-07-06
EP3544971A1 (en) 2019-10-02
US20200361906A1 (en) 2020-11-19
US11932625B2 (en) 2024-03-19
AU2017363307A1 (en) 2019-05-02
US20230227433A9 (en) 2023-07-20
JP7258748B2 (ja) 2023-04-17
CA3041563A1 (en) 2018-05-31
US11306070B2 (en) 2022-04-19
US20210317105A9 (en) 2021-10-14
WO2018098361A1 (en) 2018-05-31
JP2019535749A (ja) 2019-12-12
CA3041563C (en) 2023-10-31
US20220213067A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
US11932625B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
AU2017363313B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
AU2020263390B2 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
US12415816B2 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2016319125B2 (en) Inhibitors of cyclin-dependent kinases
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3877371A1 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
AU2020362194B2 (en) A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
WO2020097396A1 (en) Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2020301399B2 (en) HCK degraders and uses thereof
EP3313529A1 (en) Fused bicyclic pyrimidine derivatives and uses thereof
EP4598905A2 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
CA3106548A1 (en) Histone demethylase 5 inhibitors and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)